On the contrary, to exert its potential anti-lung cancer mechanism IL-33 can promote the secretion of IFN-γ and GZmB in PBMCs, thereby enhancing the cytotoxic effect of PBMCs on lung cancer cells, and downregulate PD-1 expression on CD3 positive and CD8 positive cell subsets in PMBCs, thereby improving the function of CD8+ T cells in immune responses. This evidence concerns the gene CD8A and lung carcinoma.